EZH2 copy number gain as a therapeutic target in mucosal melanoma

被引：0
|
作者：
Yu, Huan
Kong, Yan
Yan, Junya
Ma, Meng
Xu, Longwen
Yu, Jiayi
Xu, Tianxiao
Dai, Jie
Tang, Huan
Wu, Xiaowen
Chi, Zhihong
Si, Lu
Shen, Xinan
Tang, Bixia
Lian, Bin
Wang, Xuan
Li, Siming
Bai, Xue
Guo, Jun
机构：
[1] Peking Univ, Canc Hosp & Inst, Beijing, Peoples R China
[2] Peking Univ, Canc Hosp, Beijing, Peoples R China
[3] Peking Univ, Key Lab Carcinogenesis & Translat Res, Canc Hosp & Inst,Dept Renal Canc & Melanoma, Collaborat Innovat Ctr Canc Med,Minist Educ Beiji, Beijing 100142, Peoples R China
[4] Beijing Canc Hosp, Beijing, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.e21530
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e21530
引用
下载
收藏
页数：1
相关论文
共 50 条
  • [31] EZH2 as a therapeutic target for multiple myeloma and other haematological malignancies
    Rosemarie Tremblay-LeMay
    Nasrin Rastgoo
    Maryam Pourabdollah
    Hong Chang
    Biomarker Research, 6
  • [32] Frequent copy number gain of MCL1 is a therapeutic target for osteosarcoma
    Satoshi Takagi
    Mikako Nakajima
    Sumie Koike
    Miho Takami
    Yoshiya Sugiura
    Seiji Sakata
    Satoko Baba
    Ai Takemoto
    Tianyi Huang
    Yosuke Seto
    Masanori Saito
    Yuki Funauchi
    Keisuke Ae
    Kengo Takeuchi
    Naoya Fujita
    Ryohei Katayama
    Oncogene, 2025, 44 (12) : 794 - 804
  • [33] Frequent copy number gain of MCL1 is a therapeutic target for osteosarcoma
    Takagi, Satoshi
    Katayama, Ryohei
    CANCER RESEARCH, 2024, 84 (06)
  • [34] Preclinical validation of EZH2 as a therapeutic target in pediatric Ewing's sarcoma
    Pandya, Pankita H.
    Bailey, Barbara
    Elmi, Adily E.
    Bates, Heather R.
    Hemenway, Courtney N.
    Sinn, Anthony L.
    Bijangi-Vishehsaraei, Khadijeh
    Saadatzadeh, M. Reza
    Shannon, Harlan E.
    Ding, Jixin
    Marshall, Mark S.
    Ferguson, Michael J.
    Cheng, Lijun
    Li, Lang
    Murray, Mary E.
    Renbarger, Jamie L.
    Pollok, Karen E.
    CANCER RESEARCH, 2018, 78 (13)
  • [35] Somatic copy number amplification and activating somatic mutations of EZH2 Y641 drive melanoma by epigenetic remodeling.
    Hersey, Peter
    Tiffen, Jessamy
    Gallagher, Stuart
    Filipp, Fabian
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [36] Evidence that EZH2 Deregulation is an Actionable Therapeutic Target for Prevention of Prostate Cancer
    Burkhart, Deborah L.
    Morel, Katherine L.
    Wadosky, Kristine M.
    Labb, David P.
    Galbo, Phillip M.
    Dalimov, Zafardjan
    Xu, Bo
    Loda, Massimo
    Ellis, Leigh
    CANCER PREVENTION RESEARCH, 2020, 13 (12) : 979 - 988
  • [37] Epigenetics in lymphocyte and lymphoma: EZH2 as an easy-to-access therapeutic target?
    Kato, Koji
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2022, 116 (06) : 819 - 820
  • [38] The polycomb group protein EZH2 is a novel therapeutic target in tongue cancer
    Li, Zhongwu
    Wang, Yanling
    Qiu, Jing
    Li, Qiang
    Yuan, Chunping
    Zhang, Wei
    Wang, Dongmiao
    Ye, Jinhai
    Jiang, Hongbin
    Yang, Jianrong
    Cheng, Jie
    ONCOTARGET, 2013, 4 (12) : 2532 - 2549
  • [39] Epigenetics in lymphocyte and lymphoma: EZH2 as an easy-to-access therapeutic target?
    Koji Kato
    International Journal of Hematology, 2022, 116 : 819 - 820
  • [40] EZH2 as a mediator of treatment resistance in melanoma
    Tiffen, Jessamy C.
    Gallagher, Stuart J.
    Tseng, Hsin-Yi
    Filipp, Fabian V.
    Fazekas de St Groth, Barbara
    Hersey, Peter
    PIGMENT CELL & MELANOMA RESEARCH, 2016, 29 (05) : 500 - 507
12345